If a genetically or synthetically engineered organism gets into the environment, how will we tell it apart from the millions of naturally occurring microorganisms? Recently, the US government and research scientists have identified a need for new tools that can detect engineered organisms that have been accidentally or intentionally released beyond the lab. With scientists from Raytheon and other universities, WPI chemical engineer Eric Young is helping develop a detection tool based on DNA signatures.
'This study shows that [rare pulmonary side effects of brigatinib] can disappear within days despite continued exposure to the drug,' says D. Ross Camidge, M.D., Ph.D.
Researchers (UNIGE) have devised a cell co-culture platform that reproduces a patient's tumor structure in 3D. The scientists can use it to test several drugs or their combinations at different stages of the tumor's development. They now need only five days to identify which treatment will be most effective for a particular case, and the combination can then be translated for clinical practice.
The June issue of SLAS Technology features the article, 'Next Generation Compound Delivery to Support Miniaturized Biology,' which focuses on the challenges of changing the established screening paradigm to support the needs of modern drug discovery.
The June cover of SLAS Discovery features cover article 'A Perspective on Extreme Open Science: Companies Sharing Compounds without Restriction,' by Timothy M. Willson, Ph.D.
Over one-third of all FDA-approved drugs act on a specific family of proteins: G-protein coupled receptors (GPCRs). Drugs to treat high blood pressure, asthma, cancer, diabetes and myriad other conditions target GPCRs throughout the body--but a recent study shows what happens next. In results published in Cell, researchers outline the timeline of events, including precisely when and how different parts of a GPCR interacts with its G protein signaling partners.
A University of California, Riverside, research team has come up with a new approach to targeting cancer cells that circumvents a challenge faced by currently available cancer drugs.
Metals such as zinc, copper and chromium bind to and influence a peptide involved in insulin production, according to new work from chemists at UC Davis. The research is part of a new field of 'metalloendocrinology' that takes a detailed look at the role of metals in biological processes in the body.
Pain medication addiction is a major problem in the United States. UVA's Ken Hsu is seeking ways to treat pain and control inflammation without dangerous side effects.
Synthetic proteins have now been created that can move in response to their environment in predictable and tunable ways. These proteins can use their movement to disrupt lipid membranes in cells. They show promise as tools for drug delivery, and might eventually rival the efficiency of virus vehicles, but without some of their drawbacks.